Stock itci.

Even on an earnings season day when a clutch of companies notched earnings beats, Intra-Cellular Therapies' (ITCI 2.46%) first-quarter beat was notably impressive. Investors liked what they saw in ...

Stock itci. Things To Know About Stock itci.

Headquartered in Chelmsford, Massachusetts, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a sample exploration and management solutions provider for the life science market. On November 23, 2022 ...The put/call ratio of ITCI is 0.42, ... VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,591K shares representing 2.70% ownership of the company.Join Our Free Stock Market Newsletter: StockMarket.com is the #1 resource for all things Stocks. Sign up today for Free!See the latest Intra-Cellular Therapies Inc stock price (NASDAQ:ITCI), related news, valuation, dividends and more to help you make your investing decisions.

As of April 23, 2023, the average one-year price target for Intra-Cellular Therapies is 77.93. The forecasts range from a low of 56.56 to a high of $102.90. The average price target represents an ...Reported on 11/2/23. Fiscal Q3 2023 ended 9/30/23. Reported on 11/2/23. Get the latest Intra-Cellular Therapies Inc (ITCI) real-time quote, historical performance, charts, and …The stock of Intra-Cellular Therapies Inc (ITCI) has gone up by 5.10% for the week, with a -1.20% drop in the past month and a -13.62% drop in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are 3.88% for ITCI. The simple moving average fo

Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up Zacks - Wed Mar 29, 11:27AM CDT . Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.

In a report released on April 6, Brian Abrahams from RBC Capital maintained a Buy rating on Intra-Cellular Therapies ( ITCI – Research Report ), with a price target of $72.00. The company’s ...May 10, 2022 · Intra-Cellular's net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021's $52.7 million deficit. However, analysts -- and likely investors -- had been bracing for worse ... Ticker Symbol: ITCI: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0001567514: CUSIP Number: 46116X101: ISIN Number: US46116X1019ITCI stock rallied 2.2% Friday. Inspire Medical Systems ( INSP ) posted a weekly gain despite three losing days, gaining 3.8% Friday. INSP shares formed a handle and flirted with the 277.28 buy ...

Have the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for ...

Overview News Ideas Financials Technicals Forecast ITCI chart Today 0.61% 5 days −0.47% 1 month 22.49% 6 months −1.10% Year to date 12.37% 1 year …

See the latest Intra-Cellular Therapies Inc stock price (NASDAQ:ITCI), related news, valuation, dividends and more to help you make your investing decisions.NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, …Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the quote ...Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting ...Intra-Cellular Therapies Inc’s trailing 12-month revenue is $365.8 million with a -50.4% profit margin. Year-over-year quarterly sales growth most recently was 99.3%. Analysts expect adjusted earnings to reach $-2.089 per share for the current fiscal year. Intra-Cellular Therapies Inc does not currently pay a dividend.Nov 23, 2022 · Shares of Intra-Cellular Therapies (ITCI) have gained 18.4% over the past four weeks to close the last trading session at $52.87, but there could still be a solid upside left in the stock if short ...

NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual …Nov 7, 2023 · by Zacks Equity Research Published on November 07,2023. The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric ... Nov 22, 2023 · The latest Intra-Cellular Therapies stock prices, stock quotes, news, and ITCI history to help you invest and trade smarter. ITCI market cap is currently $4.31B and has a P/E ratio of -12.36. Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock.When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i...Referenced Symbols. Shares of Intra-Cellular Therapies Inc. ITCI, +3.26% jumped about 15% in premarket trading on Tuesday after the company said its experimental treatment for major depressive ...Nov 2, 2023 · The stock of Intra-Cellular Therapies Inc (ITCI) has gone up by 5.10% for the week, with a -1.20% drop in the past month and a -13.62% drop in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are 3.88% for ITCI. The simple moving average for the last 20 days is -0.20% for ITCI stock ...

Shares of Intra-Cellular Therapies (ITCI) have gained 7.7% over the past four weeks to close the last trading session at $56.01, but there could still be a solid upside left in the stock if short ...What happened. Intra-Cellular Therapies' (ITCI 0.30%) stock could have used a little financial therapy on Tuesday. The neurologic drugs-focused biotech saw its shares decline by over 14% on the ...

Intra-Cellular Therapies Inc. research and ratings by Barron's. View ITCI revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced a poster presentation on its PDE1 inhibitor program at the ongoing 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held from April 10 - 15, 2021.Intra-Cellular (ITCI) delivered earnings and revenue surprises of 33.72% and 10.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?GuruFocus Research November 2, 2023 at 10:17 AM · 2 min read Intra-Cellular Therapies Inc ( NASDAQ:ITCI) reported Q3 2023 total revenues of $126.2 …Referenced Symbols. Shares of Intra-Cellular Therapies Inc. ITCI, +3.26% jumped about 15% in premarket trading on Tuesday after the company said its experimental treatment for major depressive ...Intra-Cellular Therapies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ITCI updated stock price target summary. ITCI Profile Stock Screener Earnings Calendar Sectors Nasdaq | ITCI U.S.: Nasdaq Intra-Cellular Therapies Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023... Common Stock : ITCI : The Nasdaq Global Select Market: Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

$-1.63 Market Cap $5.46 B Shares Outstanding 96.24 M Public Float 93.82 M Yield ITCI is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short Interest (10/31/23)...

Intra-Cellular Therapies Inc. Common Stock (ITCI) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

Current. -$0.35. 1 Month Ago. -$0.41. 3 Months Ago. -$0.41. Intra-Cellular Therapies Inc. analyst estimates, including ITCI earnings per share estimates and analyst recommendations.Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) reported Q3 2023 total revenues of $126.2 million, a 75% increase compared to the same period in 2022. CAPLYTA Q3 2023 net product sales were $125.8 million, representing a 75% increase. CAPLYTA total prescriptions increased 71% in Q3 2023. The company raised its 2023 CAPLYTA net …ITCI has a Quality Grade of D, ranking ahead of 18.25% of graded US stocks. ITCI's asset turnover comes in at 0.08 -- ranking 278th of 682 Pharmaceutical Products stocks. …Nov 3, 2022 · Intra-Cellular (ITCI) delivered earnings and revenue surprises of 33.72% and 10.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($1.68) to ($0.80) per share. Intra-Cellular Therapies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More.March 31, 2023 at 11:30 AM · 4 min read. It has been about a month since the last earnings report for Intra-Cellular Therapies (ITCI). Shares have added about 20.5% in that time frame ...Find the latest dividend history for Intra-Cellular Therapies Inc. Common Stock (ITCI) at Nasdaq.com.As of April 23, 2023, the average one-year price target for Intra-Cellular Therapies is 77.93. The forecasts range from a low of 56.56 to a high of $102.90. The average price target represents an ...ITCI Profile Stock Screener Earnings Calendar Sectors Nasdaq | ITCI U.S.: Nasdaq Intra-Cellular Therapies Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023...

Intra-Cellular Therapeutics ITCI is a biopharma company focused on discovering, ... and minimal competition in its target market is likely to keep the stock afloat in the long term.On January 10, 2020, the Company completed a public offering of common stock in which the Company sold 10,000,000 shares of common stock at an offering price of $ 29.50 per share for aggregate gross proceeds of $ 295.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were …ITCI The Nasdaq Global Select Market ... Common stock, $ 0.0001 par value: 175,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, ...What happened. Intra-Cellular Therapies' (ITCI 0.30%) stock could have used a little financial therapy on Tuesday. The neurologic drugs-focused biotech saw its shares decline by over 14% on the ...Instagram:https://instagram. stocks to short this weekcobra trading platformcheap futuresnvidia share price target Intra-Cellular Therapies Inc. Common Stock (ITCI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. hero etfnvidia financials Find the latest Intra-Cellular Therapies, Inc. (ITCI) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. insurance for musical instruments The 13 analysts offering 1 year price forecasts for ITCI have a max estimate of — and a min estimate of —. Analyst rating Based on 13 analysts giving stock ratings to ITCI in the past 3 months.View the latest Intra-Cellular Therapies Inc. (ITCI) stock price, news, historical charts, analyst ratings and financial information from WSJ.March 31, 2023 at 11:30 AM · 4 min read. It has been about a month since the last earnings report for Intra-Cellular Therapies (ITCI). Shares have added about 20.5% in that time frame ...